Breakthrough Trial Transforms Treatment for Advanced Colon Cancer Patients

An international clinical trial has set a new benchmark for treating a specific type of advanced colon cancer. Researchers at VCU Massey Comprehensive Cancer Center led the effort, demonstrating that a combination of immunotherapy and chemotherapy drastically improves survival rates. The findings have already influenced major treatment guidelines in the US. The phase III trial, named ATOMIC, focused on patients with stage III dMMR (mismatch repair-deficient) colon cancer. This molecular subtype responds particularly well to immune checkpoint inhibitors like atezolizumab. Over 778 participants from centres across the US, Canada, Australia, Israel, South Africa, and several European countries—including Germany, Spain, France, and the UK—took part in the study.

Dr. Khalid Matin, associate director of global oncology at Massey, spearheaded the research. The trial was sponsored by the National Cancer Institute (NCI) and carried out in partnership with the Alliance for Clinical Trials in Oncology and Germany's Arbeitsgemeinschaft Internistische Onkologie. Industry support from Genentech, under a Cooperative Research and Development Agreement, helped accelerate the translation of results into clinical practice. Patients receiving atezolizumab alongside standard FOLFOX chemotherapy saw a 50% lower risk of cancer recurrence or death. Three-year disease-free survival rates reached 86.3% in the combined treatment group. These outcomes confirmed the value of adding immunotherapy to post-surgery adjuvant therapy for this cancer subtype. The trial operated under the NCI's Community Oncology Research Program (NCORP), with contributions from affiliates such as the Virginia Cancer Institute and Centra Health in Lynchburg. Its success has led to updated National Comprehensive Cancer Network (NCCN) guidelines, now recommending the same approach for certain stage II dMMR colon cancer patients.

The ATOMIC trial's results have reshaped treatment protocols for dMMR colon cancer. The combination of atezolizumab and chemotherapy is now a recognised standard, backed by NCCN guidelines. This shift reflects a broader move toward personalised, molecularly targeted therapies in oncology.